Document is current
Any future updates will be listed below
-
Authors
Falcón González, Alejandro
Gallegos Sancho, María Isabel
González Flores, Encarnación
Galve Calvo, Elena
Ruiz Vozmediano, Julia
Domingo García, Paloma
López Martos, Ricardo
Sánchez Rivas, Elena
Iglesias Urraca, Carmen María
Gómez Calvo, Ana Isabel
De Mariscal Polo, Amaia
Ramos-Medina, Rocío
Rivero, Maria
Martínez Marín, Virginia https://orcid.org/0009-0002-7513-2617
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 9 April 2024
Accepted: 22 July 2024
First Online: 29 August 2024
Declarations
:
: Alejandro Falcón González has served an advisory role for Pfizer, Astra-Zeneca, Novartis, Steve, and Gilead. Additionally, he has been part of the speaker bureau for Pfizer, Novartis, Lilly, Astra-Zeneca, Daichii, Eisai, Grünenthal, Seagen, and Gilead. Maria Rivero and Rocio Ramos are employees of and may own stock in Pfizer Inc. Elena Galve Calvo, María Isabel Gallegos Sancho, and Ricardo López Martos received honoraria from Pfizer for their collaboration in the preparation of this manuscript. The remaining authors declare no conflicts of interest.
: This article does not contain any studies with human participants performed by any of the authors.
: The manuscript has been read and approved for submission by all the named authors.
